Olaparib, a specific PARP inhibitor, improved both lifespan (Supplementary Table 4b) and healthspan (pumping rate, Fig. 7a) in the wrn-1(gk99) worms, indicating that PARP-dependent NAD+ consumption contributes to the phenotype of this C. elegans WS model. Here, PARP1 is linked to Werner syndrome.